MAPT and supranuclear palsy, progressive, 1: Preclinical testing demonstrated its effectiveness in reducing unbound N-terminal tau fragments in the ISF and CSF of rTg4510 human-tau-transgenic mice and the CSF of patients with PSP and AD.